NGS resequencing detected the UBA1 p.M41T (c.122 T > C) mutation confirming VEXAS syndrome and follow-up assessments identified complete molecular remission at month 21 after treatment start, in accordance with complete molecular remission of the underlying MDS. This evidence concerns the gene UBA1 and myelodysplastic syndrome.